Search

everythinglearnresearchcommunity

for

Search:↓

Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.

Some breast cancer chemotherapy can cause permanent hair loss.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Advanced nanocarrier and microneedle drug delivery methods are more effective, safer, and less invasive for treating skin diseases.

Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.

Some chemotherapy can cause permanent hair loss.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Melanocyte development from neural crest cells is complex and influenced by many factors, and better understanding could help treat skin disorders.

ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.

The p53 protein has complex, sometimes contradictory functions, including tumor suppression and promoting cell survival.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

Epidermal stem cells could lead to new treatments for skin and hair disorders.

The peptide IMT-P8 can effectively deliver proteins into the skin and cells for potential skin treatments.

Certain fungi and bacteria help orchid seeds germinate and plants grow better.

Using CRISPR for gene editing in the body is promising but needs better delivery methods to be more efficient and specific.

Nanotechnology in dermatology shows promise for better drug delivery and treatment effectiveness but requires more safety research.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

AR polyglycine repeat doesn't cause baldness.

Applying a specific inhibitor lightens skin and hair color.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

EGFR-TKIs can cause significant skin, nail, and organ side effects.

Male pattern baldness is mostly inherited, involves many genes, and is linked to other traits like early puberty and strong bones.

Hair loss can indicate underlying systemic diseases and addressing these can sometimes reverse the hair loss.

Nanocarrier-loaded gels improve drug delivery for cancer, skin conditions, and hair loss.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.